In a recent study, reported rates on emergency department utilization for hypertensive disorders of pregnancy and the postpartum period were higher in 2020 than 2006, with rates especially high among non-Hispanic Black, Hispanic, and Asian patients.
A significant increase in emergency department (ED) visits for hypertensive disorders of pregnancy and the postpartum period (HDPP) occurred in the United States between 2006 and 2020, according to a recent study published in JAMA Network Open.1
HDPP have been attributed to 6.3% of all pregnancy-related mortalities in the United States, as well as being the second leading cause of maternal death worldwide. Among US demographics, Black patient experience the highest rates of pregnancy-related mortality.
According to the American College of Obstetricians and Gynecologists, the risks of conditions such as stroke, seizure, myocardial ischemia, placental abruption, and maternal and neonatal mortality may be mitigated through severe blood pressure management in pregnancy within 30 to 60 minutes of diagnosis. This indicated the ED as a critical environment for HDPP treatment.
To evaluate the use of EDs for HDPP management in the United States, investigators conducted a cross-sectional study. The Nationwide Emergency Department Sample was assessed for HDPP-related ED use between 2006 and 2020 among pregnant or postpartum patients aged 15 to 50 years.
HDPP diagnoses were determined based on International Classification of Diseases, Ninth Revision (ICD-9) or ICD-10 codes, with total annual ED visits for HDPP reported as the primary outcome. Hospital admissions and HDPP-related ED use stratified based on race and ethnicity were reported as secondary outcomes.
Covariates included age, payment method, income quartile by zip code, hospital teaching status, and hospital geographic region. Race and ethnicity data was only available for 2019 and 2020.
There were 656,711 HDPP-related ED encounters from 2006 to 2020, increasing from 31,623 in 2006 to 55,893 in 2020. Additionally, admission for HDPP increased from 17,338 in 2006 to 43,563 in 2020, with admission rates for HDPP at 54.8% and 77.9%, respectively. In comparison, admission rates for all other primary diagnoses remained stable.
The odds of presenting to the ED for HDPP were increased compared to other diagnoses for non-Hispanic Black, Hispanic, and Asian individuals, with rates of 26.7% vs 25.4%, respectively, for non-Hispanic Black, 21.1% vs 17.6%, respectively, for Hispanic, and 4.4% vs 2.1%, respectively, for Asian patients. These individuals were also more likely to be admitted for HDPP than their non-Hispanic White counterparts.
Overall, a significant increase in US ED visits and admissions for HDPP were observed between 2006 and 2020, with ED utilization for HDPP higher among non-Hispanic Black, Hispanic, and Asian individuals. Investigators recommended “accessible, culturally competent community-level interventions for all.”
These results are supported by data from a population-based retrospective study analyzing preeclampsia trends between 2010 and 2021.2 The study included nonanomalous live births at 24 to 42 weeks’ gestation, with birth certificate data obtained from the National Vital Statistics System database.
There were 32,752,948 US births included in the final analysis. Between 2010 and 2021, chronic hypertension rates rose from 1.2% to 2.7%, while gestational diabetes rates rose from 0.7% to 1.1% This indicated increases of 1.5% and 0.4%, respectively.
Additionally, advanced maternal age rates increased from 14.7% in 2010 to 20.1% in 2021, while in vitro fertilization rates increased from 0.5% to 1.5%. Overall, a 5% increase in hypertensive disorders of pregnancy was reported, indicating a need for public health factors to reduce modifiable risk factors.
References
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Early pregnancy cannabis use high in states with recreational legalization
November 11th 2024A population-based time-series analysis California before, during and after legalization show a rising trend in women using cannabis while pregnancy especially when the state has legalized the drug.
Read More